Hedge-fund titan Julian Robertson really likes Gilead Sciences (GILD). In an interview on CNBC today, Robertson explained why he is such a fan of the stock, despite protests that its hepatitis-c treatment costs too much: David Paul Morris/Bloomberg News I’m very proud to be a shareholder of Gilead. They have really solved the Hepatitis C […]
SOURCE: Stocks to Watch – Read entire story here.
